In dementia research and in clinical practice, the COVID-19 pandemic represents an important challenge, not only for neurological staff and researchers, but above all for patients and their caregivers. It is important that the medical staff demonstrate flexibility, open-mindedness, and humanity when following patients and caregivers. It seems inevitable that caregivers will pay the highest price during this crisis.

Frontotemporal dementia (FTD), marked by impairments in behavior, language and sometimes motor function, is a common form of early-onset dementia 1 . Approximately 20-30% of FTD is caused by autosomal dominant mutations (familial, or f-FTD), usually in one of three genes: chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN) or microtubule-associated protein tau (MAPT) 2 . FTD is uniformly fatal, and there are no approved therapies; however, a growing number of new treatments targeting C9orf72, GRN and MAPT are moving into clinical trials 3,4 . Experience from Alzheimer's disease (AD), spinal muscular Temporal order of clinical and biomarker changes in familial frontotemporal dementia